Soluble lymphotoxin-β receptors as therapeutic agents for the treatment of systemic lupus erythematosus
US7309492B2 · kind B2 · utility
7Cited by
6References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 31, 2001 |
| Grant date | Dec 18, 2007 |
| Priority date | — |
| Expiry date | Dec 24, 2023 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.